Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

INTRODUCTION: The majority of breast tumors at primary diagnosis are estrogen receptor positive (ER+). Estrogen (E) mediates its effects by binding to the ER. Therapies targeting the estrogenic stimulation of tumor growth reduce mortality from ER+ breast cancer. However, resistance remains a major c...

Descripción completa

Detalles Bibliográficos
Autores principales: Weigel, Marion T, Ghazoui, Zara, Dunbier, Anita, Pancholi, Sunil, Dowsett, Mitch, Martin, Lesley-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446341/
https://www.ncbi.nlm.nih.gov/pubmed/22608253
http://dx.doi.org/10.1186/bcr3191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446341/
https://www.ncbi.nlm.nih.gov/pubmed/22608253
http://dx.doi.org/10.1186/bcr3191

Ejemplares similares